<a href="https://www.fiercebiotech.com/biotech/lilly-reneges-remainder-rigel-deal-another-blow-ripk1-inhibitors" hreflang="en">Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors</a>
Eli Lilly has terminated its licensing agreement with Rigel Pharmaceuticals for the RIPK1 inhibitor ocadusertib, citing unmet development standards, following a previous withdrawal from the CNS-focused portion of the deal. This decision adds to ongoing challenges in the RIPK1 inhibitor field, with other companies also facing setbacks.
The repeated setbacks in the development of RIPK1 inhibitors, highlighted by Eli Lilly's withdrawal from its partnership with Rigel Pharmaceuticals, suggest a critical need for reevaluation of this therapeutic approach. For professionals in healthtech and biotech, this indicates an opportunity to explore alternative pathways or targets in inflammation and autoimmune treatment, particularly with emerging interest in RIPK2 inhibitors as pursued by companies like Odyssey Therapeutics.